Skip to content
superstack
Draft entry. Written from the cited papers but not yet reviewed by a person. Check the references before relying on any claim.

MOTS-c

also Mitochondrial ORF of the 12S rRNA type-c · MOTSc · MRWQEMGYIFYPRKLR

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, not in the cell nucleus [1]. In mice, injections prevented diet-induced obesity and insulin resistance [1] and improved running capacity at every age tested [2]. In people, exercise raises the body's own MOTS-c [2], but no trial has given MOTS-c to humans, and measurements of it in blood disagree between methods [3].

Some of the most interesting biology in this group, with striking mouse results and no human treatment data at all.

2D chemical structure of MOTS-c
C101H152N28O22S22174.6 g/molCID 146675088
Preclinical12 papers · 2008–2026 · 11 journals · 4 in humans
  • meta-analysis
  • RCT
  • trial
  • observational
  • preclinical / case
  • review / patent / other
  • retracted
2008 · review · Dose translation from animal to human studies revisited.2015 · preclinical · The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.2016 · review · A simple practice guide for dose conversion between animals and human.2018 · observational · Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals.2018 · preclinical · The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.2019 · other · Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.2019 · preclinical · The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity.2019 · clinical trial · Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects.2021 · preclinical · MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.2021 · observational · A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.2023 · review · MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.2026 · review · Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
in its favour
  • + Prevented diet-induced obesity and insulin resistance in mice
  • + Improved physical capacity in young, middle-aged and old mice
  • + Exercise raises natural MOTS-c in human muscle and blood
watch for
  • Never tested as a treatment in humans
  • Blood-level measurements disagree between methods
  • The mouse studies injected it into the abdominal cavity

Overview

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is, like humanin, a signalling peptide encoded in the mitochondria's own genome. It was described in 2015 as a short reading frame inside the mitochondrial 12S rRNA gene [1]. It is present in plasma, and a review reports that levels fall with age [4].

Mouse evidence. In mice, MOTS-c injections prevented age-related and high-fat-diet insulin resistance and diet-induced obesity [1]. In obese mice it also lowered plasma metabolites linked to obesity and diabetes, and increased fat burning [5]. Daily injections improved running performance in young, middle-aged and old mice. Treatment three times a week, started in very old mice, improved grip strength, gait and walking [2].

Human evidence. No study has given MOTS-c to people. The human data are about the body's own peptide:

  • In 10 young men, a hard cycling session raised MOTS-c 11.9-fold in thigh muscle and about 1.5-fold in blood. Blood levels returned to baseline within 4 hours [2].
  • Plasma MOTS-c was similar in lean and obese adults. It tracked insulin resistance only in the lean group [6].
  • A fat infusion raised plasma MOTS-c, insulin damped the rise, and 8 weeks of moderate exercise training did not change resting levels [7].
  • An Asian-specific mitochondrial DNA variant (m.1382A>C) changes one amino acid (K14Q). It was linked to type 2 diabetes in men, and the variant peptide did not work in mice [8].

One caution applies to all the human blood data. When anti-doping chemists built a mass-spectrometry test, they could not confirm the levels a commercial ELISA kit had reported (45.9–218.5 ng/mL) [3]. Another study reported plasma levels below 1 ng/mL [6].

Mechanism

MOTS-c acts mainly on skeletal muscle. It inhibits the folate cycle and the de novo purine synthesis linked to it, and this activates AMPK, the cell's energy-shortage sensor [1]. Under metabolic stress such as glucose restriction, it moves into the nucleus in an AMPK-dependent way. There it regulates a broad set of genes, including antioxidant-response genes, and interacts with the transcription factor NRF2 [9]. The authors present this as evidence that mitochondrial DNA can directly regulate nuclear genes.

In mice it also changed skeletal-muscle metabolism and gene expression, and helped muscle cells adapt to metabolic stress [2]. Male mice responded to it but female mice did not [8].

Direct targetswhat the molecule itself binds or acts on
  • Folate cycle and de novo purine synthesisblocks
    inhibited in cells, leading to AMPK activation [1]
    moderate
Downstreamconsequences of that action, not targets of their own
  • AMPKactivates
    activated in skeletal muscle, the peptide's main target organ in mice [1]
    moderate
  • Nuclear gene expression (NRF2 / antioxidant response elements)modulates
    moves into the nucleus under metabolic stress, in an AMPK-dependent way, and regulates antioxidant-response genes with NRF2 [9]
    moderate

Dosing

as studied or commonly reported; not a recommendation

Doses below are what studies used or, where marked, what is commonly reported. None is a recommendation.No peer-reviewed human dosing data. The doses below come from animal studies or company filings; animal doses do not translate directly to people.

Intraperitoneal (animals)

  • 0.5 mg/kg (human equivalent ≈0.041 mg/kg, or ≈2.4 mg at 60 kg)
    mice on a high-fat diet
    once daily · 8 weeks
    animal study[1][10]
  • 5 mg/kg (human equivalent ≈0.41 mg/kg, or ≈24 mg at 60 kg)
    insulin sensitivity in mice
    once daily · 7 days
    animal study[1][10]
  • 5 or 15 mg/kg (human equivalent ≈0.41 or 1.2 mg/kg, or ≈24 or 73 mg at 60 kg)
    physical capacity and healthspan in young, middle-aged and old mice
    once daily, or 3 times a week in late life · 2 weeks, or until old age
    animal study[2][10]
Notes
Every dose here is from mice. No human dose has been studied. Human equivalents are body-surface-area estimates [10][11], not doses tested in people.

Pharmacokinetics

what the body does with it
MetabolismIn vitro it forms four metabolites and two oxidation products, which anti-doping tests now look for [3]

Safety

risks and cautions, not medical advice

There are no human safety data. A 2026 review of peptides sold directly to patients lists MOTS-c among unapproved compounds whose animal results look favourable but whose human safety data are scarce [12]. Anti-doping labs have developed a test for synthetic MOTS-c in plasma [3].

Adverse effects
reported, not universal
  • Not studied in humans
Cautions
who should think twice
  • Unapproved; human safety data are scarce [12]
  • Products sold online are unregulated and unverified
Limits of the evidence
what has not been shown
  • No human treatment studies; all efficacy data are from mice and cells [1][2]
  • Blood levels reported by a commercial ELISA kit could not be confirmed by mass spectrometry [3]
  • The effects in mice were seen in males but not females [8]

FAQ

Has MOTS-c been tested in humans?
Not as a treatment. Human studies have only measured the body's own MOTS-c, for example after exercise [2][6].
What does it do in mice?
It prevented diet-induced obesity and insulin resistance [1] and improved physical capacity in young and old mice [2].

References

entry last reviewed 2026-09-19
  1. [1]
    The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
    Lee C, Zeng J, Drew BG et al.Cell Metab 2015preclinical · animalPMID 25738459◌ unreviewed
  2. [2]
    MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
    Reynolds JC, Lai RW, Woodhead JST et al.Nat Commun 2021preclinical · animalPMID 33473109◌ unreviewed
  3. [3]
  4. [4]
    MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.
    Zheng Y, Wei Z, Wang TFront Endocrinol (Lausanne) 2023reviewPMID 36761202◌ unreviewed
  5. [5]
    The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity.
    Kim SJ, Miller B, Mehta HH et al.Physiol Rep 2019preclinical · animalPMID 31293078◌ unreviewed
  6. [6]
    Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals.
    Cataldo LR, Fernández-Verdejo R, Santos JL et al.J Investig Med 2018observational · humanPMID 29593067◌ unreviewed
  7. [7]
    Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects.
    Ramanjaneya M, Jerobin J, Bettahi I et al.Clin Endocrinol (Oxf) 2019clinical trial · humanPMID 31066084◌ unreviewed
  8. [8]
    A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.
    Zempo H, Kim SJ, Fuku N et al.Aging (Albany NY) 2021observational · humanPMID 33468709◌ unreviewed
  9. [9]
    The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.
    Kim KH, Son JM, Benayoun BA et al.Cell Metab 2018preclinical · cellPMID 29983246◌ unreviewed
  10. [10]
    A simple practice guide for dose conversion between animals and human.
    Nair AB, Jacob SJ Basic Clin Pharm 2016reviewPMID 27057123◌ unreviewed
  11. [11]
    Dose translation from animal to human studies revisited.
    Reagan-Shaw S, Nihal M, Ahmad NFASEB J 2008reviewPMID 17942826◌ unreviewed
  12. [12]